MiMedx(MDXG)

Search documents
MIMEDX to Participate in Upcoming Investor Conferences
GlobeNewswire News Room· 2025-05-27 12:00
MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22nd Annual Institutional Investor Conference | Minneapolis, MN1:1 sessions: Wednesday, May 28, 2025 Goldman Sachs 46th Annual Global Healthcare Conference | Miami, FL1:1 sessions: Wednesday, June 11, 2025 Northland Capital Growth Conference | Virtual1:1 sessions: Wednesday, Jun ...
MiMedx Group (MDXG) 2025 Conference Transcript
2025-05-14 01:15
MiMedx Group (MDXG) 2025 Conference May 13, 2025 08:15 PM ET Speaker0 On the wound care front, our products are found in virtually every care setting where a patient presents with a chronic or hard to heal wound, and there are lots of them as you can see from this slide. Our portfolio is comprised of a number of products, but I'd like to focus on a few highlights from our portfolio for a moment. First up, EpiFix is our flagship product for the wound market, and as I mentioned, most widely recognized efficac ...
MiMedx (MDXG) Q1 Earnings Match Estimates
ZACKS· 2025-04-30 22:15
MiMedx (MDXG) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this developer of biomaterials made from sterilized human amniotic membrane would post earnings of $0.07 per share when it actually produced earnings of $0.07, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estima ...
MiMedx(MDXG) - 2025 Q1 - Earnings Call Transcript
2025-04-30 21:32
MiMedx Group (MDXG) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Matt Notarianni - Head of Investor RelationsJoseph Capper - CEODoug Rice - Chief Financial OfficerCarl Byrnes - Managing DirectorAnthony Petrone - Managing Director Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareRoss Osborn - Analyst Operator Good afternoon and thank you for standing by. Welcome to the MieMedix First Quarter twenty twenty five Operating and ...
MiMedx(MDXG) - 2025 Q1 - Earnings Call Transcript
2025-04-30 20:30
MiMedx Group (MDXG) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good afternoon and thank you for standing by. Welcome to the MieMedix First Quarter twenty twenty five Operating and Financial Results Conference Call. At this time, participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Matt Notariani, Head of Investor Relations for M ...
MIMEDX Announces First Quarter 2025 Operating and Financial Results
GlobeNewswire News Room· 2025-04-30 20:01
Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial res ...
MiMedx(MDXG) - 2025 Q1 - Quarterly Report
2025-04-30 20:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Florida 26-2792552 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charte ...
MiMedx(MDXG) - 2025 Q1 - Quarterly Results
2025-04-30 20:00
MIMEDX Announces First Quarter 2025 Operating and Financial Results Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Com ...
MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30
Globenewswire· 2025-04-16 12:00
MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. MIMEDX is a pioneer and leader focused on helping humans heal. With more than a dec ...
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences
Newsfilter· 2025-04-10 20:01
MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. "MIMEDX's ongoing commitment to innovation and our expanding, best-in-class body of scientific and clinical evidence will be on full display at these high-profile conferences ...